TL;DR: Bipolar disorder is driven by neurobiological mechanisms — mitochondrial dysfunction, chronic neuroinflammation, and oxidative stress — that are meaningfully influenced by what you eat. The 1999 Stoll trial was the first to demonstrate that omega-3 fatty acids could improve mood stability in bipolar disorder, and subsequent research supports the value of anti-inflammatory dietary patterns, blood sugar regulation, and specific nutrients including N-acetylcysteine (NAC). Equally important are the dietary factors that can destabilise mood: caffeine-driven sleep disruption, alcohol’s interaction with mood-stabilising medications, and critical nutrient-drug interactions such as the lithium-sodium relationship and valproate-induced carnitine depletion. Weight management adds another layer of complexity, as many mood stabilisers promote weight gain. Diet is a legitimate and evidence-informed adjunctive strategy for bipolar disorder — but it is not a substitute for pharmacological and psychological treatment. Every dietary decision should be made in collaboration with your psychiatric care team.

Introduction

Bipolar disorder affects approximately 2.4 percent of the global population when including both type I and type II presentations. It is characterised by episodes of mania or hypomania alternating with periods of depression, often with intervals of relative stability between episodes. The condition is among the most biologically complex in psychiatry, involving disruptions to mitochondrial energy production, circadian rhythm regulation, neurotransmitter signalling, immune function, and oxidative stress responses.

Standard treatment relies on mood-stabilising medications — lithium, valproate, lamotrigine, and atypical antipsychotics — alongside psychotherapy and structured lifestyle management. These interventions are essential, and the evidence supporting them is strong. Yet even with optimal pharmacological treatment, many patients experience residual symptoms, breakthrough episodes, and medication side effects that significantly affect quality of life. This creates a clear rationale for examining complementary strategies that might improve outcomes without introducing new risks.

Diet is one such strategy. The biological processes that underpin bipolar disorder — mitochondrial dysfunction, inflammation, oxidative stress, and disrupted neurotransmitter metabolism — are all sensitive to nutritional inputs. This does not mean that food can treat bipolar disorder. It means that the raw materials the brain receives through diet can either support or undermine the biological stability that medication aims to achieve.

This article examines what the evidence actually shows, identifies the mechanisms that make dietary factors relevant to bipolar pathophysiology, addresses the critical interactions between diet and common bipolar medications, and provides a practical framework for implementation — all with the unambiguous caveat that dietary approaches must be adjunctive, never primary.

Bipolar Pathophysiology: Why Diet Matters

Understanding why diet is relevant to bipolar disorder requires understanding the biology of the condition itself. Three interconnected mechanisms are central.

Mitochondrial Dysfunction

Mitochondria are the primary energy-producing organelles in every cell, and the brain — consuming roughly 20 percent of total body energy — is exceptionally dependent on their function. Converging evidence from genetics, neuroimaging, post-mortem studies, and peripheral biomarker analyses points to mitochondrial dysfunction as a core feature of bipolar disorder.

Kato and Kato (2000), in a review published in Bipolar Disorders, summarised evidence that patients with bipolar disorder show decreased mitochondrial complex I activity, altered mitochondrial DNA, and impaired high-energy phosphate metabolism in the brain. Subsequent magnetic resonance spectroscopy studies have consistently found reduced N-acetylaspartate (a marker of neuronal mitochondrial function) in the prefrontal cortex and hippocampus of bipolar patients.

This is nutritionally relevant because mitochondrial function depends on a continuous supply of substrates and cofactors: CoQ10, B vitamins (particularly B2 and B3), magnesium, iron, and the fatty acids that compose mitochondrial membranes. A nutrient-poor diet can compound an already compromised mitochondrial system.

Neuroinflammation

Chronic low-grade inflammation is a consistent finding in bipolar disorder across all mood states. A meta-analysis by Goldsmith and colleagues (2016), published in Molecular Psychiatry, demonstrated that inflammatory markers — including C-reactive protein, interleukin-6, and tumour necrosis factor-alpha — are elevated during both manic and depressive episodes, and remain elevated even during euthymic (stable) periods, albeit to a lesser degree.

Inflammation in bipolar disorder is not merely a by-product of mood episodes; it appears to be a contributing driver. Pro-inflammatory cytokines alter neurotransmitter metabolism, impair neuroplasticity, disrupt circadian signalling, and directly affect the prefrontal cortex and limbic system — regions critical for mood regulation. The persistence of elevated inflammatory markers between episodes suggests that chronic, low-level immune activation may contribute to illness progression and cognitive decline over time.

Diet is one of the most potent modifiable regulators of systemic inflammation — a topic we explore in depth in our article on anti-inflammatory diet for brain health. Western dietary patterns high in ultra-processed food, refined sugar, and industrial seed oils are pro-inflammatory. Mediterranean and other whole-food-based patterns are consistently anti-inflammatory. This creates a direct mechanistic pathway through which diet can influence bipolar disease activity.

Oxidative Stress

Oxidative stress — the imbalance between reactive oxygen species (ROS) production and the body’s antioxidant defences — is substantially elevated in bipolar disorder. Andreazza and colleagues (2008), in a study published in the British Journal of Psychiatry, found that lipid peroxidation and protein oxidation were significantly increased in patients across all phases of the illness, while antioxidant enzymes were simultaneously reduced.

The brain is particularly vulnerable to oxidative damage due to its high oxygen consumption, abundant polyunsaturated fatty acid content, and relatively limited antioxidant capacity. Cumulative oxidative stress is thought to contribute to the neurodegenerative component of bipolar disorder — the grey matter volume loss and cognitive decline that can accrue over years of illness.

Dietary antioxidants — including polyphenols from berries, green tea, and extra-virgin olive oil; selenium from Brazil nuts and seafood; vitamins C and E from fruits and vegetables; and N-acetylcysteine, a precursor to the master antioxidant glutathione — can bolster the brain’s defences against oxidative damage. This is particularly relevant in a condition where oxidative stress is chronically elevated.

Omega-3 Fatty Acids: The Most-Studied Intervention

The Stoll Trial (1999)

The landmark study in bipolar disorder and nutrition is the randomised controlled trial conducted by Andrew Stoll and colleagues at Harvard, published in 1999 in the Archives of General Psychiatry. This was the first rigorous trial to test whether omega-3 fatty acid supplementation could improve the course of bipolar disorder.

Stoll enrolled 30 patients with bipolar I or II disorder, all of whom were receiving standard pharmacotherapy. They were randomised to receive either 9.6 grams per day of a fish oil concentrate (providing approximately 6.2 grams of EPA and 3.4 grams of DHA) or an olive oil placebo, for four months.

The trial was terminated early because the difference between groups was so large that continued randomisation was deemed unethical. Patients receiving omega-3s had a significantly longer period of remission before relapsing, and showed improvement across nearly every outcome measure, including the Clinical Global Impression scale and the Hamilton Depression Rating Scale. Notably, the omega-3 group showed particular benefit on depressive symptoms rather than manic symptoms.

The Stoll trial was small and its results have been described as potentially overstated due to the early termination, but it catalysed an entire research programme and remains the most frequently cited study at the intersection of bipolar disorder and nutrition.

Subsequent Meta-Analyses

The literature following Stoll has been mixed, which is important to acknowledge honestly. A Cochrane review by Montgomery and Richardson (2008) concluded that the evidence was insufficient to draw firm conclusions about omega-3s for bipolar disorder, though noted that the trend favoured benefit for depressive symptoms over manic symptoms.

Sarris and colleagues (2012), in a meta-analysis published in the Journal of Clinical Psychiatry, found a statistically significant benefit of omega-3 supplementation for bipolar depression specifically, with a moderate effect size. The benefit was not significant for mania or overall mood instability. This aligns with the broader depression literature, where EPA-predominant omega-3 formulations consistently show antidepressant effects.

A more recent systematic review by Bozzatello and colleagues (2016), published in the Journal of Affective Disorders, concluded that omega-3s appear to be a “potentially useful adjunctive treatment for bipolar depression” while acknowledging that sample sizes remain small and methodological quality varies across studies.

The pattern that emerges from the literature is consistent: omega-3 supplementation is most likely to benefit the depressive pole of bipolar disorder, effects on mania are minimal or absent, dosages in successful trials tend to be high (typically 1-2 grams of EPA per day or more), and the intervention is adjunctive to mood stabilisers — not a replacement for them. For guidance on choosing a supplement, see our fish oil supplement guide.

N-Acetylcysteine (NAC)

N-acetylcysteine is an amino acid derivative that serves as a precursor to glutathione, the body’s most important endogenous antioxidant. It also modulates glutamate signalling through the cystine-glutamate antiporter, reduces inflammatory markers, and supports mitochondrial function — addressing three of the core pathophysiological mechanisms in bipolar disorder simultaneously.

Berk and colleagues (2008), in a randomised, double-blind, placebo-controlled trial published in Biological Psychiatry, studied 75 patients with bipolar disorder who were maintained on standard medication. Participants receiving 2 grams per day of NAC for 24 weeks showed significant improvements in depression, global functioning, and quality of life compared to placebo. Notably, the benefits emerged gradually over the study period, suggesting cumulative biological effects rather than acute symptomatic relief.

A subsequent study by Berk and colleagues (2012), published in the Journal of Clinical Psychiatry, confirmed the antidepressant effects of NAC in bipolar disorder, again showing specific benefit for the depressive phase. A 2014 systematic review by Deepmala and colleagues, published in Neuroscience and Biobehavioral Reviews, included NAC among the nutritional interventions with the strongest evidence base for psychiatric conditions, noting its favorable safety profile and biological plausibility.

NAC is generally well tolerated, with gastrointestinal discomfort being the most commonly reported side effect. However, like omega-3s, it should be considered an adjunct to — not a replacement for — standard pharmacotherapy.

The Mediterranean Dietary Pattern

No randomised trial has specifically tested the Mediterranean diet as an intervention for bipolar disorder. However, the Mediterranean pattern’s relevance is supported by strong indirect evidence.

First, the Mediterranean diet is the most extensively validated anti-inflammatory dietary pattern in human nutrition research. Given that neuroinflammation is a consistent feature of bipolar disorder, any dietary approach that reliably reduces systemic inflammation has mechanistic relevance.

Second, observational studies have linked Mediterranean diet adherence to better mental health outcomes across a range of psychiatric conditions. Jacka and colleagues (2010), in a cross-sectional study published in the American Journal of Psychiatry, found that higher diet quality — defined largely by Mediterranean dietary principles — was associated with lower rates of mood and anxiety disorders in a population sample.

Third, the SMILES trial demonstrated that a modified Mediterranean diet can produce clinically meaningful improvements in unipolar depression. While bipolar depression is not identical to unipolar depression, the two share substantial biological overlap, including inflammatory pathology, oxidative stress, and monoaminergic dysfunction.

The components of the Mediterranean diet that are most relevant to bipolar disorder include: fatty fish (omega-3s), extra-virgin olive oil (oleocanthal and anti-inflammatory oleic acid), vegetables and legumes (folate, magnesium, fibre, and polyphenols), nuts and seeds (selenium, zinc, and vitamin E), and fermented foods (microbiome support). It simultaneously minimises the pro-inflammatory components — refined sugar, ultra-processed food, and excessive saturated fat — that may worsen mood instability.

Blood Sugar Stability and Mood Cycling

The relationship between glycaemic control and mood stability in bipolar disorder deserves particular attention. Rapid blood sugar fluctuations — driven by high-glycaemic-index meals, excessive sugar intake, and irregular eating patterns — produce acute changes in energy, irritability, concentration, and emotional reactivity that can mimic or amplify the sub-syndromal mood shifts common between full episodes.

There is also a well-established epidemiological connection between bipolar disorder and metabolic dysfunction. Patients with bipolar disorder have significantly higher rates of insulin resistance, metabolic syndrome, and type 2 diabetes than the general population. Calkin and colleagues (2015), in a study published in the Journal of Affective Disorders, found that insulin resistance was associated with a more chronic illness course, more frequent mood episodes, and poorer response to treatment.

Whether metabolic dysfunction is a cause, consequence, or shared-risk-factor companion to bipolar disorder remains debated. What is clear is that poor glycaemic control is associated with worse bipolar outcomes, and that stabilising blood sugar through dietary means — regular meals, adequate protein and healthy fats at each meal, complex carbohydrates rather than refined ones, and limited added sugar — can only be beneficial.

Practical blood sugar management for bipolar patients involves three principles: eating at consistent times to support circadian rhythm integrity, combining macronutrients (protein, fat, and complex carbohydrate) at each meal to slow glucose absorption, and avoiding large doses of refined sugar that produce sharp glycaemic spikes followed by reactive troughs.

Caffeine and Sleep Disruption

Sleep disruption is not merely a symptom of bipolar disorder — it is a well-established trigger for mood episodes. Shortened sleep is one of the most reliable prodromal signs of impending mania, and even partial sleep deprivation can precipitate manic episodes in vulnerable individuals. Harvey (2008), in a review published in Clinical Psychology Review, described the bidirectional relationship between sleep disturbance and mood instability as one of the defining features of the disorder.

Caffeine is the most widely consumed psychoactive substance in the world, and its primary mechanism of action — adenosine receptor antagonism — directly interferes with sleep onset, sleep depth, and total sleep duration. The half-life of caffeine varies considerably between individuals (ranging from three to seven hours in most adults, and longer in those taking certain medications), meaning that afternoon consumption can meaningfully impair sleep quality even when the individual does not subjectively feel “wired.”

For patients with bipolar disorder, caffeine management is not a trivial lifestyle consideration — it is a clinical priority. Excessive caffeine intake can erode sleep quality gradually and insidiously, creating a slow deterioration in mood stability that may not be recognised until a full episode develops. The prudent approach is to limit caffeine to moderate amounts consumed only in the morning, and to be especially vigilant during periods of elevated mood or reduced sleep, when the temptation to use caffeine to sustain energy can create a dangerous feedback loop.

Alcohol: A Destabilising Force

Alcohol and bipolar disorder is a high-risk combination. Epidemiological studies consistently show that substance use disorders co-occur with bipolar disorder at rates far exceeding the general population — with alcohol being the most commonly misused substance. Regier and colleagues (1990), in the landmark Epidemiologic Catchment Area study published in JAMA, found that over 60 percent of individuals with bipolar I disorder met criteria for a comorbid substance use disorder at some point in their lives.

The pharmacological effects of alcohol are directly relevant to mood instability. Alcohol is a central nervous system depressant that disrupts sleep architecture, impairs REM sleep, depletes B vitamins and magnesium, promotes neuroinflammation, interferes with the metabolism of mood-stabilising medications, and produces its own cycle of withdrawal-related anxiety and rebound excitability.

Alcohol also interacts dangerously with several commonly prescribed bipolar medications. It increases the sedative effects of mood stabilisers and antipsychotics, can increase lithium toxicity risk through dehydration, accelerates the hepatic metabolism of some medications while inhibiting others, and compounds the cognitive impairment that many patients already experience.

For patients with bipolar disorder, the evidence-based recommendation is straightforward: minimise or eliminate alcohol consumption. The putative cardiovascular benefits of moderate drinking (which are themselves increasingly questioned in the general population) do not apply to a population where alcohol’s neuropsychiatric harms are pronounced and well-documented.

Medication-Nutrient Interactions

Lithium and Sodium

Lithium remains the gold-standard mood stabiliser and is the only medication demonstrated to reduce suicide risk in bipolar disorder. However, lithium has a narrow therapeutic window — the difference between an effective blood level and a toxic one is small — and its renal excretion is directly linked to sodium status.

When sodium intake drops, the kidneys compensate by reabsorbing more sodium — and lithium is reabsorbed along with it, raising blood lithium levels and increasing the risk of toxicity. Conversely, a sudden increase in sodium intake can accelerate lithium excretion, potentially dropping levels below the therapeutic threshold.

This means that patients on lithium must maintain a consistent sodium intake. Drastic changes in salt consumption — whether from crash dieting, adopting a very-low-sodium health diet, excessive sweating during exercise, or dehydration from illness — can produce dangerous fluctuations in lithium levels. Symptoms of lithium toxicity include tremor, nausea, diarrhoea, confusion, and in severe cases, renal failure and cardiac arrhythmias.

The practical guidance is clear: patients on lithium should eat a consistent, moderate amount of sodium each day, maintain adequate hydration (particularly in hot weather and during exercise), and inform their prescribing physician before making any significant dietary changes.

Valproate and Carnitine

Valproate (valproic acid/divalproex sodium) is a widely prescribed anticonvulsant mood stabiliser. One of its lesser-known effects is interference with carnitine metabolism. Valproate sequesters carnitine through the formation of valproylcarnitine, which is excreted in the urine, effectively depleting the body’s carnitine stores.

Carnitine is essential for mitochondrial fatty acid oxidation — the process by which cells transport long-chain fatty acids into mitochondria for energy production. Carnitine depletion can produce fatigue, muscle weakness, and impaired mitochondrial function. In a condition where mitochondrial dysfunction is already a core pathological feature, this iatrogenic depletion is particularly concerning.

Lheureux and Hantson (2009), in a review published in Clinical Toxicology, documented the role of carnitine depletion in valproate-associated hepatotoxicity and hyperammonaemia. While routine carnitine supplementation for all valproate patients remains debated, clinicians should be aware of the interaction, and patients experiencing unexplained fatigue while taking valproate should have carnitine levels assessed.

Dietary sources of carnitine include red meat, dairy products, and to a lesser extent fish and poultry. Patients on valproate who follow vegetarian or vegan diets may be at particular risk of depletion and should discuss supplementation with their prescribing physician.

Weight Management Challenges

Weight gain is one of the most common and distressing side effects of mood-stabilising medications, and it is not merely a cosmetic concern. Lithium, valproate, olanzapine, quetiapine, and several other commonly prescribed agents promote weight gain through multiple mechanisms: increased appetite, altered lipid and glucose metabolism, sedation-related reductions in physical activity, and changes to the gut microbiome.

The metabolic consequences — insulin resistance, dyslipidaemia, metabolic syndrome, and increased cardiovascular risk — are significant. Patients with bipolar disorder already have elevated cardiovascular mortality compared to the general population, and medication-induced weight gain compounds this risk.

This creates a difficult tension. Mood stability depends on medication adherence, yet weight gain is one of the leading reasons patients discontinue their medications. A dietary approach that supports healthy weight without compromising mood stability is therefore clinically valuable.

The Mediterranean dietary pattern is well-suited to this purpose. It is nutrient-dense but not calorie-excessive, emphasises foods with high satiety value (protein, fibre, healthy fats), and has been shown to reduce metabolic syndrome markers in clinical trials. Importantly, it does not require the kind of restrictive dieting — intermittent fasting, very-low-calorie diets, ketogenic protocols — that could destabilise mood through blood sugar volatility or nutritional inadequacy.

Practical weight management strategies for bipolar patients include: prioritising protein and fibre at every meal to promote satiety, using portion-controlled nuts and seeds as snacks rather than processed alternatives, cooking with extra-virgin olive oil instead of butter or margarine, replacing sugary beverages with water or unsweetened tea, and maintaining consistent meal timing to support both metabolic and circadian stability.

A Practical Dietary Framework

The following framework synthesises the evidence into an actionable set of guidelines. It is designed to be compatible with all standard bipolar medications and to support mood stability without requiring dramatic or destabilising dietary changes.

Daily Foundation

Build each day around vegetables (five or more servings, with an emphasis on leafy greens for folate and magnesium), a quality protein source at each meal (eggs, fish, poultry, legumes, or dairy), whole grains or starchy vegetables for sustained energy, and extra-virgin olive oil as the primary added fat. Include one to two portions of berries or other deeply coloured fruit for their polyphenol content.

Weekly Priorities

Eat fatty fish at least two to three times per week — salmon, sardines, mackerel, anchovies, or herring — for EPA and DHA. Include a variety of nuts and seeds daily, with particular attention to walnuts (omega-3 ALA), pumpkin seeds (zinc, magnesium), and Brazil nuts (selenium, limited to two to three per day to avoid selenium excess). Incorporate fermented foods — yoghurt, kefir, sauerkraut, kimchi — for microbiome diversity.

What to Avoid or Limit

Minimise ultra-processed food, refined sugar, and refined carbohydrates, which promote inflammation and glycaemic instability. Limit caffeine to moderate amounts consumed before midday. Minimise or eliminate alcohol. Avoid sudden, drastic changes to salt intake if you are taking lithium.

Supplements to Discuss with Your Prescriber

Omega-3 fatty acids (1-2 grams of EPA per day) have the most evidence as a bipolar-specific adjunct, particularly for depressive symptoms. NAC (2 grams per day) has promising evidence for bipolar depression and oxidative stress. Vitamin D is worth testing and supplementing if deficient. Magnesium, widely under-consumed, supports sleep, mitochondrial function, and GABA signalling. Carnitine supplementation may be relevant for patients on valproate, particularly those with vegetarian diets or unexplained fatigue.

None of these supplements should be started or stopped without informing your psychiatric care team.

Practical Takeaway

  1. Adopt a consistent, anti-inflammatory dietary pattern based on whole foods, fatty fish, vegetables, olive oil, nuts, and legumes. The Mediterranean diet is the best-studied template, but the principles are adaptable to any food culture.

  2. Stabilise blood sugar by eating regular meals that combine protein, healthy fat, and complex carbohydrates. Avoid skipping meals and limit refined sugar, both of which can amplify sub-syndromal mood fluctuations.

  3. Protect your sleep by managing caffeine intake carefully. Limit consumption to the morning hours and reduce or eliminate it if you notice any impact on sleep quality or duration.

  4. Eliminate or substantially reduce alcohol, which destabilises mood, disrupts sleep, interacts with medications, and is associated with worse bipolar outcomes at every level of analysis.

  5. Maintain consistent sodium and fluid intake if you are taking lithium. Do not adopt very-low-sodium diets, and ensure adequate hydration during exercise and hot weather. Discuss any significant dietary changes with your prescriber.

  6. Discuss omega-3 supplementation (EPA-predominant, 1-2 grams per day) and NAC (2 grams per day) with your psychiatrist as potential adjunctive strategies, particularly if you experience predominantly depressive symptoms.

  7. Address medication-related weight gain proactively through nutrient-dense, satiating food choices rather than restrictive dieting that could compromise mood stability.

  8. Never adjust, reduce, or discontinue prescribed mood-stabilising medications based on dietary changes. Diet is an adjunct. It modulates the biological terrain in which medications work. It does not replace the medications themselves.

Frequently Asked Questions

Can diet replace medication for bipolar disorder?

No. This cannot be stated strongly enough. Bipolar disorder is a serious, chronic psychiatric condition with a significant risk of suicide, hospitalisation, and progressive functional decline if untreated. Mood-stabilising medications — particularly lithium — have robust evidence for reducing episode frequency, severity, and mortality. No dietary intervention has evidence approaching this level. Diet can support mood stability, reduce inflammation and oxidative stress, improve medication tolerability, and enhance overall health. It cannot replace pharmacological treatment. Any resource suggesting otherwise is not supported by the evidence and is potentially dangerous.

How much omega-3 should I take for bipolar disorder?

The trials showing benefit have typically used high doses — the Stoll trial used 9.6 grams of fish oil daily (providing approximately 6.2 grams of EPA and 3.4 grams of DHA). More recent research suggests that EPA specifically is the active component for mood benefits, and doses of 1-2 grams of EPA per day are generally considered the evidence-supported range. High-dose fish oil can have blood-thinning effects, so patients taking anticoagulants or those with bleeding concerns should consult their prescriber. Always inform your psychiatrist before starting supplementation, as omega-3s may interact with the effects of other medications.

Does sugar trigger manic episodes?

There is no direct evidence that sugar consumption triggers mania. However, the glycaemic instability produced by high sugar intake — rapid spikes followed by reactive drops in blood glucose — can exacerbate irritability, anxiety, impulsivity, and sleep disruption, all of which can contribute to a prodromal state in vulnerable individuals. The more robust concern is that chronic high sugar intake promotes the neuroinflammation and metabolic dysfunction that are associated with a worse overall illness course. Limiting added sugar is sensible for bipolar patients, but it should be framed as part of a comprehensive dietary strategy rather than as a specific anti-manic intervention.

Is the ketogenic diet helpful for bipolar disorder?

The ketogenic diet has generated theoretical interest for bipolar disorder based on its effects on mitochondrial function, GABA signalling, and neuronal excitability — mechanisms that overlap with those of established mood stabilisers. Case reports and small case series have described mood stabilisation in some bipolar patients following a ketogenic diet. However, no randomised controlled trials have been completed, and the diet carries significant practical risks for bipolar patients: the restrictive nature of the diet can be difficult to sustain, potential electrolyte imbalances can affect lithium levels, and the psychological stress of rigid dietary control may itself destabilise mood in some individuals. The ketogenic diet for bipolar disorder remains an experimental hypothesis, not an evidence-based recommendation.

Should I take any special precautions with diet while on lithium?

Yes. The most important precaution is maintaining consistent sodium and fluid intake. Lithium is excreted by the kidneys in competition with sodium. If your sodium intake drops suddenly (from a low-salt diet, fasting, or heavy sweating), lithium levels can rise to toxic ranges. Conversely, a sudden increase in sodium intake can drop lithium levels below therapeutic thresholds. Maintain steady hydration, avoid crash diets, be cautious with vigorous exercise in hot conditions, and inform your prescribing physician before making any significant changes to your eating patterns. Caffeine can also affect lithium levels through its diuretic effect, so caffeine intake should also remain consistent.

Sources

  • Andreazza, A. C., Kauer-Sant’Anna, M., Frey, B. N., et al. (2008). Oxidative stress markers in bipolar disorder: a meta-analysis. Journal of Affective Disorders, 111(2-3), 135-144.
  • Berk, M., Copolov, D. L., Dean, O., et al. (2008). N-acetyl cysteine for depressive symptoms in bipolar disorder — a double-blind randomized placebo-controlled trial. Biological Psychiatry, 64(6), 468-475.
  • Berk, M., Dean, O. M., Cotton, S. M., et al. (2012). The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 73(3), 264-269.
  • Bozzatello, P., Brignolo, E., De Grandi, E., & Bellino, S. (2016). Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. Journal of Clinical Medicine, 5(8), 67.
  • Calkin, C. V., Ruzickova, M., Uher, R., et al. (2015). Insulin resistance and outcome in bipolar disorder. British Journal of Psychiatry, 206(1), 52-57.
  • Deepmala, Slattery, J., Kumar, N., et al. (2015). Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neuroscience and Biobehavioral Reviews, 55, 294-321.
  • Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry, 21(12), 1696-1709.
  • Harvey, A. G. (2008). Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. American Journal of Psychiatry, 165(7), 820-829.
  • Jacka, F. N., Pasco, J. A., Mykletun, A., et al. (2010). Association of Western and traditional diets with depression and anxiety in women. American Journal of Psychiatry, 167(3), 305-311.
  • Kato, T., & Kato, N. (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders, 2(3 Pt 1), 180-190.
  • Lheureux, P. E., & Hantson, P. (2009). Carnitine in the treatment of valproic acid-induced toxicity. Clinical Toxicology, 47(2), 101-111.
  • Montgomery, P., & Richardson, A. J. (2008). Omega-3 fatty acids for bipolar disorder. Cochrane Database of Systematic Reviews, (2), CD005169.
  • Regier, D. A., Farmer, M. E., Rae, D. S., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264(19), 2511-2518.
  • Sarris, J., Mischoulon, D., & Schweitzer, I. (2012). Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. Journal of Clinical Psychiatry, 73(1), 81-86.
  • Stoll, A. L., Severus, W. E., Freeman, M. P., et al. (1999). Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry, 56(5), 407-412.